New Psychedelic Offers Rapid Relief for Depression

Antidepressants typically require four to six weeks to show effects, with repeated waits if the first drug fails, leading to treatment-resistant depression. Researchers are now investigating a single-dose psychedelic, mebufotenin, for rapid relief. A randomized control trial published in JAMA demonstrated that patients receiving one spray of mebufotenin experienced reduced depressive symptoms that lasted for eight weeks compared to a control group.

This psychedelic approach offers an alternative to slower treatments. Existing options include electroconvulsive therapy (ECT), which requires multiple sessions over weeks, and magnetic brain stimulation, also needing a lengthy course. Ketamine can offer rapid relief but its effects are temporary. Mebufotenin, with effects lasting about an hour, is being explored as a potentially faster and more efficient option.

While promising, the mebufotenin trial noted that the antidepressant effect was incomplete, with patients improving by about 30% on average. Concerns remain regarding blinding in psychedelic trials, as patients can often discern drug administration. Regulators like the FDA have previously rejected MDMA for PTSD due to such issues. Psilocybin has shown modest success in trials, but its longer session times led to the focus on shorter-acting mebufotenin.

In India, psychedelics like psilocybin and DMT are banned. Experts suggest ketamine, which is already prescriptible off-label, as a more accessible option for treatment-resistant depression. While some research supports ketamine's use, more robust studies are needed. The Indian Psychiatric Society recommends ketamine, acknowledging limitations in long-term data, while ongoing trials explore its use as a first-line treatment.